News & Views | Telix Pharmaceuticals Limited

IPAX-1 Study of TLX101 Investigational Glioblastoma Therapy Published in Neuro-Oncology Advances

Telix today announces that the Company’s IPAX-1 Phase I study has been published in Neuro-Oncology Advances, confirming the safety and tolerability profile, and early efficacy of TLX101 therapy, in combination with external beam radiation therapy (EBRT) in recurrent glioblastoma (GBM), the most common and aggressive form of primary brain cancer.

Telix Submits NDA for TLX101-CDx (Pixclara®) Brain Cancer Imaging Agent

Telix today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX101-CDx, (Pixclara®[1], 18F-floretyrosine or 18F-FET), an investigational PET[2] agent for the characterisation of progressive or recurrent glioma (brain cancer) from treatment related changes in both adult and pediatric patients.

Telix Announces Reorganisation to Deliver on Strategic Priorities

Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led radiopharmaceutical company committed to precision oncology.

Telix 2024 Half-Year Results: Strong Commercial Revenue and Profit Growth to Support Strategic Priorities

Telix today announces its financial results for the half-year ended 30 June 2024. All figures are in AU$ unless otherwise stated.

Telix Half-Year Results 2024 Investor Webcast Notification

Telix today advises that it will release its financial results for the half-year ended 30 June 2024 on Thursday 22 August 2024.

Telix Successfully Prices A$650 Million Convertible Bonds

Telix is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as “convertible bonds” (Convertible Bonds), are convertible into fully paid ordinary shares in Telix (Ordinary Shares). The Offering received strong support from eligible investors globally.

Q2 2024 Revenue and Business Highlights, Guidance Upgrade

Telix today provides an update on its revenue and operational performance for the quarter ended 30 June 2024 (Q2 2024).

Telix Welcomes CMS Proposal to Improve Payment for Specialised Diagnostic Radiopharmaceuticals

Telix today welcomes proposed changes announced by the Centers for Medicare & Medicaid Services (CMS) for the Hospital Outpatient Prospective Payment System (OPPS) rule to improve payments for diagnostic radiopharmaceuticals for Medicare patients in the United States (U.S.), facilitating continued patient access after transitional pass-through payment status expires.

Telix Elects to Withdraw from Proposed U.S. Listing

Telix today announces that it has elected to withdraw its proposed initial public offering (IPO) in the United States.

Telix Completes TLX250-CDx (Zircaix®) BLA Submission for Kidney Cancer Imaging

Telix today announces that it has completed the submission of a Biologics License Application (BLA) to the United States (U.S.) Food and Drug Administration (FDA) for its investigational radiodiagnostic PET agent, TLX250-CDx (Zircaix®, 89Zr-DFO-girentuximab), for the characterisation of renal masses as clear cell renal cell carcinoma (ccRCC).